KLOW Blend
Multi-component research blend
A research-supplier blend referenced in recovery and inflammation research, combining multiple repair-related peptides.
Also referenced as: KLOW
Overview
KLOW is a marketed multi-component research blend. It is typically described as combining GHK-Cu (copper tripeptide), KPV (an alpha-MSH fragment), and a BPC-157 / TB-500 combination. Exact composition can vary by supplier and it is not a naturally occurring substance.
At a glance
What KLOW Blend does
KLOW is a multi-peptide research blend typically combining KPV, GHK-Cu, BPC-157, and TB-500, though exact components and ratios vary by supplier. Its design intent is to stack complementary repair and anti-inflammatory mechanisms so that inflammation control, tissue remodeling, and vascularization are addressed together. Each component brings a distinct action: KPV supplies alpha-MSH-derived anti-inflammatory signaling that suppresses NF-kB and pro-inflammatory cytokines; GHK-Cu (a copper-binding tripeptide) supports extracellular-matrix remodeling, collagen and elastin synthesis, wound healing, and antioxidant activity; BPC-157 adds angiogenic and cytoprotective repair signaling; and TB-500 adds actin-regulated cell migration plus its own angiogenic and anti-inflammatory effects.
The combined rationale is a broad regenerative and anti-inflammatory profile: KPV calms the inflammatory milieu, GHK-Cu rebuilds and reorganizes the extracellular matrix, and BPC-157 and TB-500 drive vascularization and cell migration into the repair zone. On paper the components' actions overlap and reinforce one another across skin, gut, and connective-tissue repair contexts, which is why the blend is marketed for recovery and tissue-health research.
As with all such stacks, the honest evidence position is that KLOW itself has not been studied as a combination in controlled trials. What exists is the separate preclinical (and, for GHK-Cu, some cosmetic/dermatologic human) literature on each ingredient. Because supplier formulations differ, the actual contents and proportions are not standardized, and any whole-blend effects are extrapolated from the components rather than directly demonstrated.
Effects reported in research
- KPV component contributes alpha-MSH-derived anti-inflammatory action, suppressing NF-kB signaling and pro-inflammatory cytokines (preclinical).
- GHK-Cu component supports extracellular-matrix remodeling, collagen/elastin synthesis, and antioxidant activity, with some human dermatologic data.
- BPC-157 component adds angiogenic and cytoprotective tissue-repair signaling (animal/in-vitro).
- TB-500 component adds actin-regulated cell migration plus angiogenic and anti-inflammatory effects (animal/in-vitro).
- Multiple components independently promote angiogenesis and connective-tissue repair, reinforcing wound-healing endpoints (preclinical).
- Combines anti-inflammatory control with matrix rebuilding and vascularization, giving a broad regenerative rationale across skin, gut, and soft tissue.
- The KLOW combination itself has no controlled clinical trials; all evidence is preclinical and inferred from the separate ingredients.
- Exact components and ratios vary by supplier, so the blend is not standardized (commonly KPV + GHK-Cu + BPC-157 + TB-500).
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
As a blend, KLOW combines the documented properties of its components: GHK-Cu's copper-delivery and tissue-remodeling signaling, KPV's melanocortin-pathway anti-inflammatory activity, BPC-157's angiogenesis and growth-factor-related repair signaling, and TB-500's actin-regulation and cell-migration effects. These properties come from separate preclinical and cosmetic research; the combined formulation is not independently validated in controlled human trials.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which KLOW Blend appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- A multi-component blend generally combining GHK-Cu, KPV, and a BPC-157/TB-500 pairing
- Combines the documented properties of its individual components
- Exact composition and ratios can vary between sources
- The blend as a whole has no dedicated clinical validation
- Contains research-only components not approved as drugs (GHK-Cu is used cosmetically)
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. KLOW Blend is a research compound.
Because KLOW is a fixed multi-peptide blend, research protocols dose by total reconstituted volume based on the labeled composition rather than by adjusting individual peptides. These are reference figures for research context only, not dosing guidance for humans; verify component amounts against the COA.
- Example vial composition: ~80 mg total (~50 mg GHK-Cu, ~10 mg BPC-157, ~10 mg TB-500, ~10 mg KPV) - varies by supplier
- Dosing is anchored to the fixed blend ratio; per-peptide amounts follow whatever the vial's labeled composition delivers
Composition and ratios vary by vendor - the COA is authoritative. Fixed ratio means components cannot be adjusted independently. Research-only blend.
How it compares
KLOW is a broader combination than two-component blends, pairing a copper cosmetic tripeptide and an anti-inflammatory MSH fragment with repair-focused peptides.
Blend components
This entry documents a research-supplier blend combining the following. Each component is documented as its own PeptiDex entry where available:
Commonly studied alongside
Compounds frequently researched together with KLOW Blend in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Compare and calculate
Side-by-side pages for the pairings the literature already documents for KLOW Blend, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
KLOW Blend sits in the Healing & Recovery area of the PeptiDex library.
- Entry type: Research-supplier blend
- Healing & Recovery category hub →
- Browse the full library →
- Glossary of terms →
Where researchers source KLOW Blend
For researchers studying KLOW Blend, third-party suppliers such as Practically Natty Peptides offer research-grade material, third-party tests every batch and provides Certificates of Analysis on request, and ship from the US.
View research-supplier listing →
Outbound link to a third-party research supplier. Inclusion does not constitute endorsement; all editorial content is developed independently.
Frequently asked questions
What is the KLOW blend and what does the name mean?
KLOW is a four-component research blend most commonly composed of KPV, GHK-Cu, BPC-157, and TB-500. The name is generally described as KPV added to the GLOW blend, where GLOW is GHK-Cu + BPC-157 + TB-500. Exact composition and ratios vary by supplier, so the vial's COA is the authoritative source.
What is each component in KLOW contributing?
In research terms, GHK-Cu (copper tripeptide) is studied for gene-expression modulation and tissue remodeling, BPC-157 for angiogenic and nitric-oxide signaling, TB-500 for actin dynamics and cell migration, and KPV for anti-inflammatory NF-kB modulation. The blend is used to study combined tissue-repair and inflammation pathways rather than any single target. All such effects are preclinical.
What is a typical KLOW vial composition?
One commonly cited configuration is an 80 mg vial containing roughly 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV. Other vendors use different totals and ratios, so this should be verified against the specific product's certificate of analysis rather than assumed.
How is KLOW reconstituted and stored?
As a lyophilized multi-peptide blend it is reconstituted with bacteriostatic water added gently down the vial wall and swirled rather than shaken, then refrigerated at 2-8 C and protected from light. Because it contains GHK-Cu (a copper complex), light protection and gentle handling are emphasized. Label the vial with the reconstitution date.
Is KLOW an approved drug?
No. KLOW is a research-only blend and none of its components are approved for the combined use it represents; several components are prohibited in sport under WADA. Any regenerative or anti-inflammatory claims are based on preclinical work on the individual peptides.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.
References
No indexed primary literature located for this compound as of 2026-07-28. PubMed was searched for work specific to KLOW Blend and none was found.
PeptiDex states this plainly rather than citing a study of a different compound to fill the space — the same null-not-guessed rule the specification table follows. See the editorial policy.